AusCann Group Holdings Ltd (ASX: AC8) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Auscann Group Holdings Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $36.57 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 440.55 million
Earnings per share -0.030
Dividend per share N/A
Year To Date Return -57.44%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

AusCann Group Holdings Ltd (ASX: AC8)
Latest News

AC8 ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About AusCann Group Holdings Ltd

Auscann Group Holdings Ltd (ASX: AC8) is a pharmaceutical company based in Western Australia. Its focus is on developing, producing and distributing a range of cannabinoid treatments for use in Australia and internationally.

According to Auscann, the company’s products are the result of a stringent development program that aims to produce stable and effective cannabinoid-based medicines. Auscann also seeks to generate clinical evidence supporting the efficacy of its products to support further market penetration.

Whilst working directly with patients, Auscann’s primary focus is on providing healthcare professionals with optimal treatment solutions to help them better care for their patients. The company also provides healthcare professionals with the tools to personalise and adjust dosage and treatment programs for each individual.

AusCann was readmitted to the ASX in early 2017 after it was acquired by the already listed company TW Holdings Limited. In the months following, the Auscann share price surged by nearly 200%. Within 12 months, the Auscann share price had gone on to deliver growth of nearly 500% over its ASX readmittance value. Since then however, the Auscann share price has trended lower and has not traded over $1 since late 2018.

AC8 Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Dec 2021 $0.08 $0.00 0.00% 331,773 $0.08 $0.09 $0.08
02 Dec 2021 $0.09 $0.00 0.00% 225,858 $0.08 $0.09 $0.08
01 Dec 2021 $0.08 $0.00 0.00% 315,818 $0.08 $0.08 $0.08
30 Nov 2021 $0.08 $0.00 0.00% 223,586 $0.09 $0.09 $0.08
29 Nov 2021 $0.08 $0.00 0.00% 899,286 $0.09 $0.09 $0.08
26 Nov 2021 $0.09 $0.00 0.00% 275,116 $0.09 $0.09 $0.09
25 Nov 2021 $0.09 $0.00 0.00% 1,002,413 $0.09 $0.09 $0.09
24 Nov 2021 $0.09 $0.00 0.00% 1,590,493 $0.09 $0.09 $0.09
23 Nov 2021 $0.09 $-0.01 -10.20% 1,357,468 $0.10 $0.10 $0.09
22 Nov 2021 $0.10 $-0.01 -9.52% 191,058 $0.10 $0.10 $0.10
19 Nov 2021 $0.11 $0.01 10.10% 210,651 $0.10 $0.11 $0.10
18 Nov 2021 $0.10 $0.00 0.00% 605,330 $0.10 $0.11 $0.10
17 Nov 2021 $0.10 $0.00 0.00% 203,728 $0.11 $0.11 $0.10
16 Nov 2021 $0.11 $0.00 0.00% 805,853 $0.11 $0.11 $0.11
15 Nov 2021 $0.11 $0.00 0.00% 523,590 $0.11 $0.11 $0.11
12 Nov 2021 $0.10 $0.01 10.53% 485,932 $0.10 $0.11 $0.10
11 Nov 2021 $0.10 $0.00 0.00% 191,031 $0.10 $0.10 $0.10
10 Nov 2021 $0.10 $0.00 0.00% 891,770 $0.10 $0.10 $0.10
09 Nov 2021 $0.10 $0.00 0.00% 979,167 $0.10 $0.11 $0.10
08 Nov 2021 $0.10 $0.00 0.00% 169,952 $0.10 $0.10 $0.10
05 Nov 2021 $0.10 $0.00 0.00% 126,835 $0.10 $0.10 $0.10

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
04 Nov 2021 Krista Bates Transfer 427 $44,000
Off-market transfer.
04 Nov 2021 Krista Bates Transfer 427 $44,000
Off-market transfer.
14 May 2021 Geoff Starr Buy 100 $11,500
On-market trade.
15 Apr 2021 Robert (Max) Johnston Buy 110 $15,400
On-market trade.
18 Mar 2021 Krista Bates Buy 292 $42,412
As advised by the company. Shares acquired under the Scheme of
Arrangement with CannPal Animal
Therapeutics Ltd.
18 Mar 2021 Christopher (Chris) Mews Buy 279 $40,554
As advised by the company. Shares acquired under the Scheme of
Arrangement with CannPal Animal
Therapeutics Ltd (ASX:CP1) under which
CP1 shareholders received 1.3 new AC8
shares for every 1 CP1 share held at the
record date.
18 Mar 2021 Robert (Max) Johnston Buy 390 $56,550
As advised by the company. Shares acquired under the Scheme of
Arrangement with CannPal Animal
Therapeutics Ltd.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Ms Krista Bates Non-Executive DirectorInterim Chairperson Dec 2019
Ms Bates has 21 years of expertise in the legal market. She was a Partner at leading Western Australian law firm Lavan specialising in Corporate law and was
Head of Mining & Resources and the Medical Cannabis Group.
Mr Geoff Starr Non-Executive Director Apr 2021
MR Starr brings over 35 years of executive experience to the company, 15 years of which was at Managing Director or CEO level, gained all around the world, but
especially in Asia, Europe and Australia/New Zealand.
Mr Robert Clifford Non-Executive Director Apr 2021
Mr Clifford has more than 25 years of experience in Food and beverage industry. Mr Clifford has held various executive management positions in Perth, Canberra and Macau.
Dr Kathryn (Kate) Claire Adams Non-Executive Director Apr 2021
Dr Adams is an entrepreneur and Veterinarian. Dr Adams has held senior
leadership roles for the Federal Attorney-General's Portfolio including as an Analyst, Principal Adviser and Chief of Staff for a number of Royal Commissions.
Mr Christopher (Chris) Lee Mews Non-Executive Director Dec 2019
Mr Mews is an experienced non-executive director with over 20 years in the financial services sector, having held senior positions in finance, corporate secretarial and compliance in listed and unlisted companies.
Mr Layton Patrick Mills Chief Executive Officer Mar 2021
-
Ms Susan Patricia Park Company Secretary Oct 2016
-
Mr Quentin Heath Megson Chief Financial OfficerJoint Company Secretary Feb 2019
-
Layton Patrick Mills Chief Executive Officer
-
Quentin Heath Megson Chief Financial OfficerJoint Company Secretary
-
Susan Patricia Park Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
The Trust Company (Australia) Limited (MOF A/C) 56,379,750 12.80%
Citicorp Nominees Pty Limited 12,263,518 2.78%
Mr Layton Patrick Mills (DJs Family A/C) 11,387,582 2.58%
Ms Tania Maree Vidovic (Star V Family A/C) 7,400,874 1.68%
Merrill Lynch (Australia) Nominees Pty Limited 5,754,883 1.31%
Mr George Chien Hsun Lu & Mrs Jenny Chin Pao Lu 4,958,999 1.13%
Pepaanne Pty Ltd (The Chapman Family A/C) 4,600,000 1.04%
Mr Warren Sidney Langman 4,235,928 0.96%
HSBC Custody Nominees (Australia) Limited 3,340,101 0.76%
Bnp Paribas Nominees Pty Ltd (Ib Au Noms Retailclient Drp) 2,813,910 0.64%
Bnp Paribas Nominees Pty Ltd Acf Clearstream 2,639,184 0.60%
Ajava Holdings Pty Ltd 2,600,000 0.59%
Miss Xiaodan Fu 2,577,402 0.59%
Mr George Chien-Hsun Lu 2,569,999 0.58%
Bnp Paribas Noms Pty Ltd (DRP) 2,563,129 0.58%
Marcus Kelly Property Developments Pty Ltd 2,500,000 0.57%
Wil & Jack Pty Ltd (Wil & Jack Family A/C) 2,348,106 0.53%
Lus International Limited 2,339,999 0.53%
Mr John Andrew Rodgers (John Rodgers Family A/C) 2,316,372 0.53%
Ms Kate Eloise Toft (Johnstone Family A/C) 2,237,521 0.51%

Profile

since

Note